Peng He

nanjing geneseeq technology inc

H指数:20

被引数:944

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study

血浆cfDNA片段组学在多中心研究中实现了膀胱癌的非侵入性检测和术前风险分层

Cancer Letters

IF10.1

2026-09-180

OAAI

A cfDNA fragmentomics-based liquid biopsy assay for early detection of oral cancer

基于cfDNA片段组学的液体活检检测口腔癌早期诊断的实验

BMC Cancer

IF3.4

2026-08-150

Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or younger

建议对HER2阳性且年龄在35岁或以下的患者进行临床TP53基因检测。

npj Genomic Medicine

IF4.8

2025-07-020

OAAI

Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort study

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2025-05-010

PRE

Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis

发现一种用于治疗溃疡性结肠炎的新型CRBN招募cGAS PROTAC降解剂

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-02-261

PRE

Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer

BREAST CANCER RESEARCH AND TREATMENT

IF3

2025-01-050

PRE

Comparative Biomechanical Stability of the Fixation of Different Miniplates in Restorative Laminoplasty after Laminectomy: A Finite Element Study

椎板切除术后修复椎板成形术中不同微型钢板固定的生物力学稳定性比较: 有限元研究

BIOENGINEERING-BASEL

IF3.7

2024-05-201

OAAI

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment

发现用于胰腺癌治疗的高选择性和有效的STAT3抑制剂

ACS CENTRAL SCIENCE

IF10.4

2024-02-1010

OAAI

Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis

延长辅助内分泌治疗对激素受体阳性早期乳腺癌的疗效和安全性比较: 贝叶斯网络meta分析

BREAST CANCER RESEARCH AND TREATMENT

IF3

2023-10-032

PRE

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-05-223

PRE

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-05-027

PRE

High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients

高白细胞线粒体DNA拷贝数导致乳腺癌患者预后不良

BMC CANCER

IF3.4

2023-04-254

OAAI

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway

CANCER LETTERS

IF10.1

2023-04-0114

PRE

Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-10-2510

PRE

Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer

1，5-二芳基-1，2，4-三唑衍生物作为myoferlin抑制剂的发现及其在胰腺癌中的抗肿瘤作用

FUTURE MEDICINAL CHEMISTRY

IF3.4

2022-09-272

PRE

Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-09-1411

PRE

Discovery of 2-Amino-3-cyanothiophene Derivatives as PotentSTAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-04-2719

PRE

Nanoparticles and photochemistry for native-like transmembrane protein footprinting

NATURE COMMUNICATIONS

IF15.7

2021-12-1416

OAAI

Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study

ANNALS OF ONCOLOGY

IF65.4

2021-09-011

OAAI

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-05-2762

OAAI

Peng He

个人简介

教育背景

工作经历

荣誉奖项

研究方向